Ascend Wellness Holdings (AAWH) Other Non-Current Liabilities (2022 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Other Non-Current Liabilities came in at $224.3 million in Q1 2026, up 29.41% year-on-year from $173.3 million in Q1 2025, and up 6.58% quarter-over-quarter from $210.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Ascend Wellness Holdings' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $224.3 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 29.41% year-over-year to $224.3 million in Q1 2026; TTM through Mar 2026 was $224.3 million, a 29.41% increase from a year earlier, with the FY2025 full-year figure at $210.5 million, up 32.46% from the prior year.
- Other Non-Current Liabilities improved to $224.3 million in Q1 2026 per AAWH's latest filing, from $210.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $224.3 million in Q1 2026 and bottomed at $1.8 million in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $94.2 million (2023), against an average of $93.1 million.
- Across the five-year window, Other Non-Current Liabilities jumped 719.98% in 2024 and tumbled 98.68% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $15.1 million in 2022, then soared by 494.29% to $89.6 million in 2023, then jumped by 77.34% to $158.9 million in 2024, then soared by 32.46% to $210.5 million in 2025, then grew by 6.58% to $224.3 million in 2026.
- Per Business Quant, the three latest AAWH Other Non-Current Liabilities figures stand at $224.3 million (Q1 2026), $210.5 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 224.31 Mn |
| Dec 31, 2025 | 210.46 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 184.46 Mn |
| Mar 31, 2025 | 173.34 Mn |
| Dec 31, 2024 | 158.89 Mn |
| Sep 30, 2024 | 136.69 Mn |
| Jun 30, 2024 | 122.47 Mn |
| Mar 31, 2024 | 98.72 Mn |
| Dec 31, 2023 | 89.60 Mn |
| Sep 30, 2023 | 16.67 Mn |
| Jun 30, 2023 | 16.07 Mn |
| Mar 31, 2023 | 15.57 Mn |
| Dec 31, 2022 | 15.08 Mn |
| Sep 30, 2022 | 14.84 Mn |
| Jun 30, 2022 | 10.00 Mn |